InflaRx (NASDAQ:IFRX) Announces Earnings Results, Beats Estimates By $0.04 EPS

Key Points

• InflaRx reported quarterly EPS of $(0.02), beating analyst estimates of $(0.06) by $0.04.
• The company sees a potential $1.5 billion–$2 billion peak-sales opportunity for izicopan in ANCA-associated vasculitis and plans two Phase II studies, with initial readouts potentially arriving in 2027–2028.
• InflaRx reported EUR 153.3 million in cash and a runway through 2029, but its stock fell 13% to $1.54; analysts maintain a “Moderate Buy” consensus with a $7.43 average price target.

InflaRx (NASDAQ:IFRX - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.04, FiscalAI reports.

Here are the key takeaways from InflaRx's conference call:

• InflaRx sees a $1.5 billion–$2 billion peak-sales opportunity for izicopan in ANCA-associated vasculitis, based on physician market research and potential use in the 70%–80% of patients with renal involvement.
• The company believes izicopan could offer faster onset, higher exposure, lower pill burden, and fewer drug–drug interaction concerns than avacopan; 197 subjects have been dosed to date without reported safety signals of concern, although longer-term data remain limited.
• InflaRx plans two parallel phase II AAV studies: a randomized, placebo-controlled renal vasculitis trial focused on eGFR, proteinuria, hematuria, and remission, and an open-label study designed to test rapid corticosteroid tapering and potential replacement.
• External experts emphasized that AAV remains a serious, frequently relapsing disease with substantial kidney damage, infection risk, and glucocorticoid toxicity, while prior avacopan data support steroid-sparing and renal-function benefits but remain clouded by a retracted publication and ongoing FDA availability questions.
• InflaRx reported EUR 153.3 million in cash and a runway through 2029, with additional programs planned in atypical hemolytic uremic syndrome, IgA nephropathy, and rapidly progressive IgA nephropathy; initial readouts are expected as early as 2027–2028.

InflaRx Stock Down 13.0%

IFRX stock traded down $0.23 during trading on Tuesday, reaching $1.54. The company's stock had a trading volume of 548,560 shares, compared to its average volume of 1,042,877. InflaRx has a 1 year low of $0.80 and a 1 year high of $2.95. The company has a market capitalization of $226.36 million, a P/E ratio of -2.63 and a beta of 2.59. The company's fifty day moving average is $1.86 and its 200-day moving average is $1.63.

Analyst Ratings Changes

A number of brokerages have commented on IFRX. Weiss Ratings restated a "sell (d-)" rating on shares of InflaRx in a research report on Monday, September 21st. Needham & Company LLC assumed coverage on InflaRx in a research report on Monday, September 14th. They set a "buy" rating and a $8.00 price objective on the stock. Cantor Fitzgerald boosted their price objective on InflaRx from $4.00 to $6.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Finally, Zacks Research lowered shares of InflaRx from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 25th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.43.

InflaRx Company Profile

InflaRx N.V. NASDAQ: IFRX is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company's research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.

The company's lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.